Physician profile
Harminder Kaur
NPI 1083702799
$8,373.87
in general payments reported to CMS, 2019-2025
31 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,648 · 2020: $608 · 2021: $650 · 2022: $495 · 2023: $426 · 2024: $232 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $971.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $5,135.65 | 2019-2023 | Wegovy, Saxenda |
| Takeda Pharmaceuticals U.S.A., INC. | $581.82 | 2019-2023 | Trintellix |
| Astrazeneca Pharmaceuticals Lp | $564.45 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $291.82 | 2020-2025 | Kisunla |
| Otsuka America Pharmaceutical, INC. | $197.77 | 2024-2025 | Rexulti |
| Gilead Sciences, INC. | $181.84 | 2019-2020 | |
| Pfizer INC. | $179.63 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $178.88 | 2019-2022 | |
| Glaxosmithkline, LLC. | $160.83 | 2019-2020 | |
| Axsome Therapeutics, INC. | $118.75 | 2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $112.79 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $86.78 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $68.45 | 2022-2023 | Quviviq |
| Eisai INC. | $61.44 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $47.42 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $39.32 | 2019-2020 | |
| Nabriva Therapeutics, Plc | $36.19 | 2020-2021 | |
| Horizon Therapeutics Plc | $35.04 | 2020 | |
| Janssen Pharmaceuticals, INC | $34.05 | 2023 | Xarelto |
| Janssen Biotech, INC. | $33.00 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $32.69 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $29.32 | 2022 | |
| Assertio Therapeutics, INC. | $24.55 | 2020 | |
| Shire North American Group INC | $24.41 | 2019 | |
| Pharming Healthcare, INC. | $21.25 | 2024 | Ruconest |
| Paratek Pharmaceuticals, INC. | $19.94 | 2021 | |
| Bio Products Laboratory USA, INC. | $17.20 | 2021 | |
| Alfasigma USA, INC. | $16.58 | 2021 | |
| Abbott Laboratories | $15.78 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harminder Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.